tVNS for migraine

The short version

If you live with migraine that has not responded well enough to medication, tVNS is worth knowing about. It is a small device with an electrode worn in the ear that delivers gentle electrical pulses to a branch of the vagus nerve. The goal is to reduce how often migraines happen and how severe they are. It is used alongside your existing treatment, never as a replacement. You use it at home.

The tVNS device is a certified medical device with a specific regulatory approval for migraine, manufactured in Germany and distributed in the UK by Anatomical Concepts UK.

What we are trying to solve

Migraine is the second leading cause of disability worldwide, and the leading cause among women aged 15 to 49. In the UK, roughly 10 million adults live with migraine. About 1 million of those have chronic migraine, defined as 15 or more headache days per month.

Current preventive medications help many people, but not enough of them. Topiramate achieves a meaningful response in roughly 35 to 45% of patients but causes cognitive side effects that many people find unacceptable. Beta-blockers cause fatigue. Amitriptyline causes drowsiness. Even the newer CGRP monoclonal antibodies, which represent a genuine advance, achieve a 50% improvement in only 27 to 61% of patients and are available on the NHS only after failure of three or more previous preventive treatments.

On top of this, about half of people with chronic migraine who attend specialist headache clinics also have medication overuse headache: a pattern in which taking acute painkillers too often actually makes the headaches worse. Any treatment that does not contribute to medication overuse has intrinsic value for this group.

tVNS sits in a useful gap. It is non-invasive, home-based, has no drug interactions, and cannot cause medication overuse. It is not a first-line treatment, and the evidence base is at an earlier stage than for epilepsy or depression, but the signals are real and the mechanistic rationale is strong.

How it works, in plain English

The vagus nerve connects the brainstem to most of the body's major organs. A small branch of it surfaces in the outer ear, on a ridge called the cymba conchae. The tVNS device clips into the ear and delivers gentle electrical pulses to this branch.

Those pulses travel up to the brainstem and interact with the pain-processing systems that are directly involved in migraine. Three things happen that matter.

First, the vagus nerve and the trigeminal nerve (the nerve most responsible for migraine pain) converge in the brainstem. Stimulating the vagus nerve appears to quiet the trigeminal pain pathway, reducing the firing of the neurons that drive the headache.

Second, vagal stimulation inhibits a process called cortical spreading depression, the slowly moving wave of brain activity that underlies migraine aura and is thought to trigger the headache itself. Brain imaging and animal studies have confirmed this effect.

Third, the vagus nerve increases the release of serotonin and norepinephrine from brainstem centres that regulate pain. These are the same pathways targeted by triptans (the acute migraine drugs) and by some preventive medications.

There is also an anti-inflammatory component. Migraine involves neuroinflammation, and vagal stimulation reduces the production of inflammatory molecules through a well-characterised pathway called the cholinergic anti-inflammatory reflex.

What the evidence shows

The evidence for tVNS in migraine comes from two complementary approaches: auricular tVNS (through the ear, which is what the tVNS device uses) and cervical tVNS (a handheld device pressed against the neck). Both confirm that vagal stimulation has genuine effects on migraine.

Auricular tVNS (through the ear):

The key trial in chronic migraine found that stimulation at 1 Hz reduced headache days by an average of 7 days per month. Both treatment groups also showed significant improvements in migraine-related disability.
A meta-analysis confirmed that low-frequency auricular tVNS significantly reduces headache days and headache intensity.
An important finding from the migraine literature is that 1 Hz stimulation may work better than the 25 Hz used for epilepsy. This is not yet confirmed by large trials, but it has practical implications for how the device is set up.

Cervical tVNS (the gammaCore device, for context):

In the PRESTO trial of acute migraine treatment, significantly more people achieved pain freedom at 30 and 60 minutes with the device than with sham.
The PREMIUM II prevention trial did not meet its main measure: the average reduction in monthly migraine days was not significantly different from sham, and the trial was stopped early and left underpowered by the COVID-19 pandemic. However, significantly more people on active treatment than on sham achieved at least a 50% reduction in migraine days (about 45% versus 27%).
Patients who have migraine with aura appeared to respond particularly well, which fits the proposed mechanism.

What the evidence does not yet show:

The auricular approach does not yet have a large sham-controlled trial specifically for chronic migraine. The key auricular trial compared two active frequencies rather than active versus sham, which means the absolute effect size is harder to pin down. This is the most important evidence gap, and we think it is important to state it clearly. The evidence is encouraging, the mechanism is strong, and the safety profile is excellent, but the field needs larger, more rigorous auricular-specific trials.

What to expect

You keep taking your current medication. tVNS is an add-on, not a replacement. Any medication changes should be discussed with your clinician.
You use the device at home. Based on the strongest evidence, a typical migraine protocol is 4 hours daily at low frequency (1 Hz). Your clinician may adjust this. You can use the device while reading, resting, or going about your day.
You keep a headache diary. Record your migraine days, headache days, and how many acute medications you take. This is the information you and your clinician need to judge whether the treatment is working.
You wait, and you persist. Allow at least eight to twelve weeks of consistent use before judging the response. As with other neuromodulation approaches, the benefit builds over time.
You review with your clinician. At regular intervals, look at the diary together and decide whether to continue.

If you have migraine with aura, you may be particularly likely to respond. This is consistent with the mechanism: tVNS inhibits cortical spreading depression, which is the process thought to cause aura. It is not a guarantee, but it is a biologically coherent reason for optimism in this group.

Who it is not for

tVNS is intended for adults aged 18 and over, and it is generally well tolerated, but there are some situations where it is not suitable. Do not use tVNS if you:

are pregnant
have an active implant, such as a cochlear implant, an implanted vagus nerve stimulator, or a cardiac pacemaker
have a cerebral shunt (for example, for hydrocephalus)
have sore or broken skin where the electrode would sit

If you have a heart rhythm problem, talk to your doctor before using tVNS.

Most side effects are mild and local, usually tingling or redness at the electrode site, and tend to settle with use. Less commonly, people report headache, dizziness, or ear or neck discomfort. Serious side effects are uncommon; the Instructions for Use list the full range, and you should report anything that concerns you to your clinician.

Common questions

Can tVNS replace my migraine medication? That is a conversation for you and your clinician. tVNS is designed to be used alongside your existing prevention and acute treatment. Some people do reduce their medication over time, but this should always be done under clinical guidance.

Does it help with acute attacks? The strongest evidence for acute treatment comes from cervical tVNS (the gammaCore device), not from auricular tVNS. The tVNS device distributed by Anatomical Concepts is designed primarily for preventive use through daily sessions, rather than as an acute "rescue" device during an attack.

Will it stop medication overuse headache? tVNS does not contribute to medication overuse, because it is not a painkiller. If part of your problem is that you are taking too many acute medications, tVNS may help by reducing the number of migraine days, which in turn reduces the need for acute treatment. This is a plausible benefit, but it has not been specifically tested in a dedicated trial.

How does it compare with Botox injections? OnabotulinumtoxinA (Botox, the PREEMPT protocol) requires specialist clinic visits every 12 weeks. In around 45% of patients it achieves at least a 50% reduction in headache days by 24 weeks. tVNS is home-based and daily. No head-to-head trials exist, so we cannot say which is more effective for you. The practical difference is that tVNS does not require clinic visits or injections.

What to do next

Talk to your neurologist, headache specialist, or GP. Ask whether they are open to neuromodulation as an addition to your current plan.
Read the clinicians' page for the deeper evidence, including stimulation parameters and study details.
Contact us. If you have questions about whether tVNS is likely to be relevant for your migraines, we will give you a straight answer.

Contact Anatomical Concepts UK

For clinicians: the full evidence page

How to access tVNS

This page is for information only. It is not medical advice. Any decision about tVNS should be made with your clinician, who knows your full medical history.

tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.